Dapagliflozin: all 489 studies that test it
Page 4 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- Dapagliflozin Effect on Rheumatic Mitral StenosisStatus unknownNCT05618223Phase 3
- Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial RemodelingStatus unknownNCT05606718Phase 4
- Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary SyndromeCompletedNCT05601336Phase 3
- Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 DiabetesStatus unknownNCT05591235Phase 3
- proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2Active, not recruitingNCT05590143Phase 4
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated AlbuminuriaCompletedNCT05570305Phase 2
- Effect of Dapagliflozin on VT in Patients With Heart Failure.Status unknownNCT05550441Phase 4
- PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive CareTerminatedNCT05468203Phase 3
- Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT05459701Phase 4
- Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 DiabetesCompletedNCT05457933Phase 4
- Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 DiabetesStatus unknownNCT05440591Phase 4
- Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney InjurySuspendedNCT05435235Phase 4
- A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One TabletCompletedNCT05429593Phase 1
- Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic PatientsCompletedNCT05424315Phase 2/3
- Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection FractionStatus unknownNCT05420285Phase 2
- A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.CompletedNCT05411965Phase 1
- Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)CompletedNCT05406505Phase 2/3
- A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult VolunteersCompletedNCT05403281Phase 1
- Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic PatientsTerminatedNCT05392959Phase 4
- Obesity Treatment to Improve DiabetesCompletedNCT05390307Not applicable
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKDActive, not recruitingNCT05374291Phase 3
- Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis PatientsCompletedNCT05343078Phase 4
- Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction PatientsCompletedNCT05335629Not applicable
- The Effect of Inflammation in Heart FailureWithdrawnNCT05330013Phase 2
- DAPAgliflozin for Renal Protection in Heart Transplant RecipientsActive, not recruitingNCT05321706Phase 3
- Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus PatientsStatus unknownNCT05310916Phase 3
- A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver DiseaseStatus unknownNCT05308160Phase 3
- TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertensionTerminatedNCT05268926Phase 2
- Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single ComponentsCompletedNCT05266404Phase 1
- Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.Status unknownNCT05262257Early Phase 1
- Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic SteatohepatitisCompletedNCT05254626Phase 2
- Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis TreatmentStatus unknownNCT05250752Phase 2
- Short-term Use of Dapagliflozin to Protect Kidney Function in CKD PatientsStatus unknownNCT05225077Phase 4
- Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial DysfunctionStatus unknownNCT05217654Phase 1
- Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney DiseaseCompletedNCT05196347Phase 3
- SGLT2 Inhibition in HemodialysisCompletedNCT05179668Phase 2
- Dapagliflozin in Pulmonary Arterial HypertensionCompletedNCT05179356Phase 2
- The Safety of Dapagliflozin in Hemodialysis Patients With Heart FailureStatus unknownNCT05141552Not applicable
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two DiabetesStatus unknownNCT05109949Phase 3
- Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in CystinuricsWithdrawnNCT05058859Phase 2
- Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial InfarctionCompletedNCT05050500Phase 4
- The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic DysfunctionStatus unknownNCT05045274Not applicable
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver TransplantationCompletedNCT05042505Not applicable
- Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast CancerStatus unknownNCT05025735Phase 2
- Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCTStatus unknownNCT05014594Phase 2
- Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy ParticipantsCompletedNCT04991571Phase 1
- Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart FailureCompletedNCT04956809Phase 2
- Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)CompletedNCT04930549Phase 2
- The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis PatientsCompletedNCT04923295Not applicable
- Neoadjuvant SGLT2 Inhibition in Localized Prostate CancerTerminatedNCT04887935Phase 1
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed ConditionsCompletedNCT04881006Phase 1
- Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting ConditionsCompletedNCT04880993Phase 1
- Dapagliflozin on Volume Vascular Outcomes.CompletedNCT04869124Phase 4
- DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceStatus unknownNCT04860011Phase 3
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult VolunteersCompletedNCT04856969Phase 1
- A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.CompletedNCT04856007Phase 1
- Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary InterventionStatus unknownNCT04806633Early Phase 1
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialStatus unknownNCT04796428Phase 4
- Dapagliflozin in Non-diabetic Stage IV CKDCompletedNCT04794517Phase 2
- Effect of Dapagliflozin on LV Remodeling Post AMIStatus unknownNCT04783870Phase 4
- Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting ListWithdrawnNCT04782245Phase 2
- Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.Status unknownNCT04780438Early Phase 1
- Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal DiseaseWithdrawnNCT04764097Phase 2/3
- EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.CompletedNCT04743453Phase 4
- Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEFStatus unknownNCT04739215Phase 4
- Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)CompletedNCT04717986Not applicable
- Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .CompletedNCT04707352Phase 3
- Dapagliflozin After Transcatheter Aortic Valve ImplantationCompletedNCT04696185Phase 4
- SGLT2-Inhibitors for Sleep Apnea in Heart FailureWithdrawnNCT04640493Phase 2
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.CompletedNCT04634500Phase 3
- Dapagliflozin Treatment in Type 2 DiabetesCompletedNCT04620590Phase 4
- The DAPA-MEMRI TrialCompletedNCT04591639Not applicable
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan TherapyCompletedNCT04575675Phase 4
- Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®Status unknownNCT04570865Phase 4
- Efficacy and Safety of Dapagliflozin in Children With ProteinuriaCompletedNCT04534270Phase 4
- Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection FractionStatus unknownNCT04475042Phase 2
- Semaglutide and Dapagliflozin in Diabetic Patients With Different PathophysiologyActive, not recruitingNCT04451837Phase 2
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCompletedNCT04393246Phase 2/3
- Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart FailureCompletedNCT04385589Phase 4
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedNCT04356742Phase 3
- Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac SurgeryStatus unknownNCT04340908Phase 4
- Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration TrialActive, not recruitingNCT04333823Phase 3
- Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery DiseaseTerminatedNCT04330079Phase 4
- Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical TrialStatus unknownNCT04304560Phase 2
- Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic AgentsStatus unknownNCT04287387Phase 4
- A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin AloneStatus unknownNCT04255238Phase 3
- Phthalates Exposure in Type 2 Diabetic Patients and Diuretic TherapyStatus unknownNCT04242758Phase 4
- Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)TerminatedNCT04234867Phase 1
- Dapagliflozin Efficacy and Action in PCOSCompletedNCT04213677Phase 3
- The Effects of SGLTi on Diabetic CardiomyopathyStatus unknownNCT04200586Phase 4
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes MellitusStatus unknownNCT04195243Phase 3
- Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 DiabetesCompletedNCT04193566Phase 4
- Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes MellitusStatus unknownNCT04120623Phase 4
- Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor TreatmentCompletedNCT04080518Phase 4
- Dapagliflozin in Physical Exercise in Type 1 DiabetesCompletedNCT04049110Phase 3
- Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 DiabetesCompletedNCT04035031Phase 3
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes MellitusStatus unknownNCT04014192Phase 4
- Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)CompletedNCT04004793Phase 4
- SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 DiabetesCompletedNCT03982381Phase 4
- Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes PatientsCompletedNCT03982238Phase 4